These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21855111)

  • 1. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
    Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
    Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome.
    Davidson B; Risberg B; Goldberg I; Nesland JM; Berner A; Tropé CG; Kristensen GB; Bryne M; Reich R
    Am J Surg Pathol; 2001 Dec; 25(12):1493-500. PubMed ID: 11717538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma.
    Brusegard K; Stavnes HT; Nymoen DA; Flatmark K; Trope CG; Davidson B
    Virchows Arch; 2012 Feb; 460(2):193-202. PubMed ID: 22249560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
    Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.
    Nymoen DA; Holth A; Hetland Falkenthal TE; Tropé CG; Davidson B
    Mol Cancer; 2015 Feb; 14():44. PubMed ID: 25889687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
    Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
    Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
    Davidson B; Trope' CG; Wang TL; Shih IeM
    Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
    Davidson B; Baekelandt M; Shih IeM
    Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.
    Vettukattil R; Hetland TE; Flørenes VA; Kærn J; Davidson B; Bathen TF
    Hum Pathol; 2013 Sep; 44(9):1859-66. PubMed ID: 23656974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
    Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
    Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
    Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
    Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
    Davidson B; Bock AJ; Holth A; Nymoen DA
    Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
    Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
    Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
    Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
    Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
    Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
    Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble AXL is ubiquitously present in malignant serous effusions.
    Flem Karlsen K; McFadden E; Flørenes VA; Davidson B
    Gynecol Oncol; 2019 Feb; 152(2):408-415. PubMed ID: 30448261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.
    Slipicevic A; Holth A; Hellesylt E; Tropé CG; Davidson B; Flørenes VA
    Gynecol Oncol; 2014 Oct; 135(1):118-24. PubMed ID: 25093290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
    Broner EC; Tropé CG; Reich R; Davidson B
    Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
    Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
    Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.